Differential change in extraocular muscle volume after teprotumumab for thyroid eye disease
Teprotumumab significantly reduces EOM volumes, CAS, and proptosis in TED. Weak correlations with clinical outcomes suggest that additional factors, such as orbital fat, influence treatment response.
Authors
- Marissa K. Shoji (ORCID: https://orcid.org/0000-0002-6297-4674)
- Evan Walker (ORCID: https://orcid.org/0000-0001-8566-0371)
- David B. Granet (ORCID: https://orcid.org/0000-0001-8011-2480)
- Megan R. Routzong (ORCID: https://orcid.org/0000-0001-5551-1156)
- Jolene C. Rudell (ORCID: https://orcid.org/0000-0003-3022-4649)
- Don O. Kikkawa
- Hanna Richkind (ORCID: https://orcid.org/0009-0009-6728-4398)
Institutions
- Fleet Science Center (US)
- University of California San Diego (US)
- The California Eye Institute (US)
- Smith-Kettlewell Eye Research Institute (US)
Publication Details
- Journal
- Orbit
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1080/01676830.2025.2574861
- Citations
- 1
- Primary Topic
- Ophthalmology and Eye Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.47